AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Efficacy and Safety of Ciclesonide Administered With or Without Different Spacers in Patients With Asthma (12 to 75 y) (BY9010/M1-145)
Phase 3
Completed
- Conditions
- Asthma
- First Posted Date
- 2005-09-14
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00163436
- Locations
- 🇮🇹
Altana Pharma/Nycomed, Verona, Italy
A Phase IIA Study of BMS-512148 to Assess Safety, Exposure, and Biological Effects in Stable Type 2 Diabetic Subjects
- First Posted Date
- 2005-09-13
- Last Posted Date
- 2016-10-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 47
- Registration Number
- NCT00162305
- Locations
- 🇺🇸
Local Institution, San Antonio, Texas, United States
Seroquel in Acute Mania: Study to Investigate if Valproate Add-On Therapy is Superior to Quetiapine Monotherapy in Acutely Manic Patients
Phase 4
Terminated
- Conditions
- Bipolar Disorder
- Interventions
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 17
- Registration Number
- NCT00139074
- Locations
- 🇩🇰
Research Site, Kolding, Denmark
🇩🇰Researcg Site, Svendborg, Denmark
An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2005-08-26
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 137
- Registration Number
- NCT00135330
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Study Evaluating Gefitinib (IRESSA®) in Subjects With Solid Malignancies That Are Locally Advanced, Recurrent or Metastatic
- First Posted Date
- 2005-08-09
- Last Posted Date
- 2009-04-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 66
- Registration Number
- NCT00127829
- Locations
- 🇺🇸
Research Site, Palm Springs, California, United States
Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-03
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1035
- Registration Number
- NCT00121641
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
Phase 3
Completed
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2015-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1462
- Registration Number
- NCT00121667
- Locations
- 🇨🇳
Local Institution, Taipei, Taiwan
Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
Phase 3
Completed
- Conditions
- Cerebral StrokeIschemic Attack, Transient
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2010-11-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1700
- Registration Number
- NCT00119626
- Locations
- 🇬🇧
Research Site, Glasgow, United Kingdom
Seroquel in Bipolar Depression Versus SSRI
Phase 3
Completed
- Conditions
- Bipolar DisorderBipolar DepressionDepression
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 676
- Registration Number
- NCT00119652
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
Efficacy and Safety of Quetiapine Fumarate (SEROQUEL®) in the Treatment of Alcohol Dependency in Patients With Bipolar Disorder
Phase 3
Completed
- Conditions
- Bipolar I DisorderAlcohol Dependence
- First Posted Date
- 2005-06-17
- Last Posted Date
- 2013-01-04
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 350
- Registration Number
- NCT00114686
- Locations
- 🇺🇸
Research Site, Milwaukee, Wisconsin, United States
© Copyright 2025. All Rights Reserved by MedPath